Related Experiment Video

Updated: Jun 14, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

525

Renalase Potential as a Marker and Therapeutic Target in Chronic Kidney Disease

Larisa Florina Serban-Feier1,2, Elena Cuiban1,2, Elena Bianca Gogosoiu2

  • 1Department of Nephrology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Biomedicines
|August 29, 2024
PubMed

Insights

Renalase, an enzyme primarily from the kidney, may help manage hypertension and cardiovascular disease in chronic kidney disease (CKD) patients. Further research is exploring its potential as a biomarker and therapeutic target in CKD.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Hypertension and cardiovascular disease are major complications of chronic kidney disease (CKD).
  • These conditions contribute to mortality and disease progression in CKD patients.
  • The interaction between the heart and kidneys in CKD is not fully understood.

Purpose of the Study:

  • To review clinical evidence on renalase in patients with chronic kidney disease.
  • To evaluate the potential of renalase as a diagnostic marker in CKD.
  • To explore renalase as a therapeutic target for managing cardiovascular aspects of CKD.

Main Methods:

  • Systematic review of clinical studies involving subjects with chronic kidney disease.
  • Analysis of data on renalase levels and their correlation with hypertension and cardiovascular outcomes.
  • Assessment of preclinical and clinical data regarding renalase's physiological effects.

Main Results:

  • Renalase, an enzyme predominantly secreted by the kidney, plays a role in regulating blood pressure.
  • Evidence suggests renalase may influence sympathetic nervous system activity.
  • The enzyme's levels and function in CKD patients require further investigation.

Conclusions:

  • Renalase may be a key factor in the interplay between kidney and heart health in CKD.
  • Renalase holds promise as a potential biomarker for cardiovascular risk in CKD.
  • Targeting renalase could offer a novel therapeutic strategy for managing hypertension and cardiovascular disease in CKD.

Keywords:
cardiovascular diseasechronic kidney diseasehypertensionrenalase

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.6K
Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney10:00

Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney

Published on: October 12, 2015

11.9K

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
277
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
153